Paul J Leslie Iii, LPC | |
410 University Pkwy., Suite 2300, Aiken, FL 29801-6807 | |
(803) 335-1219 | |
(803) 335-1689 |
Full Name | Paul J Leslie Iii |
---|---|
Gender | Male |
Speciality | Counselor - Professional |
Location | 410 University Pkwy., Aiken, Florida |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1528199825 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | (* (Not Available)) | Secondary |
101YP2500X | Counselor - Professional | 5158 (South Carolina) | Primary |
Mailing Address | Practice Location Address |
---|---|
Paul J Leslie Iii, LPC 410 University Pkwy, Suite 2300, Aiken, SC 29801-6807 Ph: (803) 335-1219 | Paul J Leslie Iii, LPC 410 University Pkwy., Suite 2300, Aiken, FL 29801-6807 Ph: (803) 335-1219 |
News Archive
Japanese pharmaceutical company Takeda on Friday announced that it has acquired from 3M the rights for a drug, called R-851, to treat cervical dysplasia and "high-risk" human papillomavirus infection, Reuters reports.
The drug levosimendan did not improve survival for patients with decompensated heart failure when compared with a more widely-used treatment for this condition, dobutamine, according to a study in the May 2 issue of JAMA.
A new study from Spain finds that narrow band imaging appears to be a less time-consuming and equally effective alternative to chromoendoscopy for the detection of dysplasia (abnormal growths) in patients with long-standing inflammatory bowel disease.
Crucell, the Dutch biotechnology company, "said on Tuesday it had agreed with Britain's GlaxoSmithKline to jointly develop a malaria vaccine candidate, without disclosing financial details," Reuters reports (Gray-Block, 4/6).
› Verified 8 days ago